Press Release|Articles|December 3, 2024
Camber Pharmaceuticals Announces Addition of Decitabine for Injection
Listen
0:00 / 0:00
Key Takeaways
- Decitabine for Injection targets adult patients with myelodysplastic syndromes, including various subtypes and chronic myelomonocytic leukemia.
- The product is offered in a 50 mg single-dose vial, enhancing treatment accessibility.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.
Decitabine for Injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for Injection is available in a 50 mg Single-Dose Vial.
To find out more information on Decitabine for Injection please visit:
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5